2016
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab
SZTURZ, Petr, Pol SPECENIER, Carl VAN LAER, Danielle VAN DEN WEYNGAERT, Bob CORTHOUTS et. al.Základní údaje
Originální název
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab
Autoři
SZTURZ, Petr (203 Česká republika, garant, domácí), Pol SPECENIER (56 Belgie), Carl VAN LAER (56 Belgie), Danielle VAN DEN WEYNGAERT (56 Belgie), Bob CORTHOUTS (56 Belgie), Laurens CARP (56 Belgie), Eric VAN MARCK (56 Belgie), Olivier VANDERVEKEN (56 Belgie) a Jan B. VERMORKEN (56 Belgie)
Vydání
European Archives of Oto-Rhino-Laryngology and Head & Neck, NEW YORK, SPRINGER, 2016, 0937-4477
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 1.660
Kód RIV
RIV/00216224:14110/16:00090827
Organizační jednotka
Lékařská fakulta
UT WoS
000375607700038
Klíčová slova anglicky
Tonsil cancer; Positron emission tomography; Taxanes; Targeted therapy; Epidermal growth factor receptor inhibitor
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 9. 2016 15:20, Soňa Böhmová
Anotace
V originále
In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.